STOCKWATCH
·
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Open OfferApr 28, 2026, 07:44 PM

ORKA Prices Upsized Public Offering of 9.66M Shares at $72.50

AI Summary

Oruka Therapeutics, Inc. announced the pricing of its upsized underwritten public offering of 9,660,000 shares of common stock at $72.50 per share. The offering is expected to generate gross proceeds of approximately $700.4 million for the company. Underwriters have also been granted a 30-day option to purchase up to an additional 1,449,000 shares. The offering is anticipated to close around April 30, 2026.

Key Highlights

  • Oruka priced an upsized public offering of 9,660,000 shares of common stock.
  • The offering price to the public is $72.50 per share.
  • Gross proceeds are expected to be approximately $700.4 million.
  • Underwriters have a 30-day option to purchase up to an additional 1,449,000 shares.
  • The offering is expected to close on or about April 30, 2026.
ORKA
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Oruka Therapeutics, Inc.

Price Impact